Is Egrifta (Tesamorelin) Legal in Colorado?

The Short Answer: Tesamorelin Is Legal in Colorado

Egrifta is a federally approved prescription drug. Colorado follows federal law on drug approval, meaning a valid prescription written by a Colorado-licensed clinician is the only legal requirement to obtain Egrifta in the state. No additional Colorado statute restricts its use.

The FDA granted approval on August 13, 2010, under NDA 022505, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy [1]. That approval makes tesamorelin a legitimate, on-label pharmaceutical product. Colorado does not maintain a separate state-level drug approval pathway, so federal approval translates directly into state-level legality.

What "Legal" Means in Practice

Legal, in this context, means three things. First, the drug may be manufactured and distributed by the NDA holder (Theratechnologies). Second, a licensed Colorado prescriber may write a prescription for it without facing regulatory action. Third, a licensed Colorado pharmacy may dispense it to a patient holding that prescription.

Colorado's Pharmacy Practice Act (CRS Title 12, Article 280) requires that any prescription drug dispensed to a Colorado resident be prescribed by a properly licensed practitioner and dispensed by a licensed pharmacy [2]. Egrifta satisfies both conditions when the standard prescription workflow is followed.

Federal vs. State Framework: Why Both Matter

The FDA sets the baseline for what drugs may legally exist in commerce [3]. States then layer their own pharmacy board regulations and medical practice acts on top. Colorado's State Board of Pharmacy (DORA) does not add restrictions to FDA-approved drugs beyond standard dispensing rules. Prescribers must follow Colorado's Medical Practice Act (CRS 12-240-101) [2], which requires a valid prescriber-patient relationship and clinical indication before a prescription is written.

FDA Approval: The Foundation of Legal Status

Understanding why Egrifta is legal requires a look at the NDA history. Theratechnologies submitted NDA 022505 to the FDA's Division of Metabolism and Endocrinology Products. The agency approved tesamorelin 2 mg (Egrifta SV) based on two key Phase III trials (INCITE and a companion study) totaling more than 500 HIV-positive adults [4].

The INCITE Trial Data

In the INCITE trial (N=251), patients randomized to tesamorelin 2 mg once daily for 26 weeks showed a statistically significant reduction in visceral adipose tissue (VAT) compared to placebo (mean VAT reduction of 18.1% vs. 5.1% placebo, P<0.0001) [5]. At 52 weeks, patients who continued tesamorelin maintained VAT reduction while placebo-switchers showed rebound accumulation [5].

The FDA's prescribing information, available on the FDA label repository, records the most common adverse events as injection-site reactions (25.3%), peripheral edema (6.0%), and arthralgia (5.9%) [1].

Egrifta SV vs. Original Egrifta

The reformulated product, Egrifta SV (2 mg/vial), replaced the original 1 mg formulation in 2019 under a supplemental NDA. Egrifta SV uses room-temperature-stable lyophilized powder, improving patient handling [6]. Both formulations carry the same active ingredient, tesamorelin acetate, and the same indication. Colorado prescribers may write for either formulation, though Egrifta SV is now the commercially available version.

Compounded Tesamorelin in Colorado: A Different Legal Picture

FDA-approved Egrifta and compounded tesamorelin are not legally equivalent. This distinction matters for Colorado patients who may encounter compounding pharmacies offering tesamorelin at lower cost.

The FDA 503B Bulks List

The FDA's 503B Outsourcing Facilities Bulks List governs which bulk drug substances outsourcing facilities may use in compounding [7]. Tesamorelin is listed as a substance under evaluation, meaning the FDA has not nominated it as appropriate for 503B compounding at this time. That status creates a meaningful regulatory barrier for outsourcing facilities [7].

Under Section 503A of the Food, Drug, and Cosmetic Act, traditional compounding pharmacies may compound drugs only when a commercially available product does not meet a specific patient's needs, such as an allergy to an excipient or a required non-standard dose [8]. Because Egrifta SV is commercially available in a standard dose, the bar for 503A compounding is high. A Colorado compounding pharmacy that produces tesamorelin without a documented clinical rationale for deviation from the commercial product risks FDA enforcement action [8].

Colorado Board of Pharmacy Position

Colorado's Board of Pharmacy follows federal law on compounding. The board's regulations (4 CCR 723-21) require that compounded products not be copies of commercially available FDA-approved drugs [2]. A compounding pharmacy in Denver, Colorado Springs, or anywhere else in Colorado therefore cannot legally produce bulk tesamorelin as a routine alternative to Egrifta SV. Patients who receive a compounded tesamorelin offer should ask the pharmacy to document the specific clinical justification and confirm the pharmacy holds a valid Colorado license.

The HealthRX clinical team uses a three-question compliance screen for any compounded peptide inquiry: (1) Is there a commercially available FDA-approved version? (2) Has the prescriber documented a patient-specific medical reason the commercial version cannot be used? (3) Is the compounding pharmacy licensed under Colorado 4 CCR 723-21? If any answer is unfavorable, the team defaults to the FDA-approved product.

Is Tesamorelin a Controlled Substance in Colorado?

No. Tesamorelin is not scheduled under the federal Controlled Substances Act (CSA) [9]. The DEA's scheduling system covers substances with abuse potential, and growth-hormone-releasing factor analogs have not been placed on any DEA schedule [9].

Colorado's Controlled Substances Act (CRS 18-18-101 et seq.) mirrors the federal schedule and adds a small number of state-specific substances [10]. Tesamorelin does not appear on any Colorado-specific schedule. Prescribers do not need DEA registration to prescribe Egrifta, and pharmacies do not need Schedule II-V dispensing infrastructure.

Anti-Doping Context: Colorado Athletes

While tesamorelin is not a controlled substance, it is prohibited in sport. The World Anti-Doping Agency (WADA) includes GH-releasing peptides and GH-releasing hormones on its Prohibited List (class S2) [11]. Colorado athletes competing under WADA-signatory organizations should be aware of this separate prohibition, which is an anti-doping rule rather than a criminal law. Possession and use by non-competitive individuals remain fully legal.

How to Get Egrifta (Tesamorelin) in Colorado

Getting a legal Egrifta prescription in Colorado follows a standard prescription pathway. There is no state-specific permit or special registration required beyond a valid clinician license.

Step 1: Establish a Prescriber-Patient Relationship

Colorado's Medical Practice Act requires a prescriber to evaluate a patient before writing a prescription [2]. For tesamorelin, this means the clinician must document the HIV-positive diagnosis, confirm the presence of excess abdominal fat consistent with lipodystrophy, and rule out contraindications (active malignancy, hypopituitarism, pregnancy) [1].

Colorado allows telehealth prescribing under HB21-1196, which brought the state into conformance with national telehealth standards after the COVID-19 public health emergency [12]. A Colorado-licensed telehealth provider may evaluate and prescribe Egrifta without an in-person visit, provided they complete an appropriate clinical assessment.

Step 2: Off-Label Use Considerations

FDA approval covers HIV-associated lipodystrophy only. Some clinicians prescribe tesamorelin off-label for non-HIV patients with visceral adiposity or age-related GH decline. Colorado law does not prohibit off-label prescribing per se, but the prescriber must document clinical reasoning and obtain informed consent [2]. The FDA has not approved any additional indications, and off-label use is the prescriber's professional responsibility [3].

Research published in the Journal of Clinical Endocrinology and Metabolism (Falutz et al., 2010, N=412) documented significant trunk fat reduction in HIV-positive patients over 52 weeks, forming part of the evidentiary basis for FDA approval [13]. A separate study by Stanley et al. (2014, N=88) explored tesamorelin in non-HIV older adults and found modest GH and IGF-1 increases [14]. Neither trial establishes a new FDA indication.

Step 3: Filling the Prescription in Colorado

Licensed retail pharmacies and specialty pharmacies may dispense Egrifta to Colorado residents. Because of cold-chain and patient-training requirements, many prescribers route patients to specialty pharmacies that provide injection education and insurance navigation support. Theratechnologies operates a patient-support program called EGRIFTAssist that helps Colorado patients with prior authorization and co-pay assistance [6].

Colorado Medicaid (Health First Colorado) covers Egrifta for qualifying HIV-positive members, subject to prior authorization criteria that include a confirmed HIV diagnosis and documented lipodystrophy [15].

Colorado Telehealth and Tesamorelin Prescribing

Telehealth has changed access to specialty medications across Colorado, particularly in rural counties where endocrinologists and HIV specialists may not be locally available. Under Colorado's telehealth parity law, insurance plans that cover Egrifta for in-person visits must provide the same coverage for telehealth-initiated prescriptions [12].

What a Telehealth Visit for Egrifta Should Include

A proper telehealth evaluation for tesamorelin should cover:

• Confirmed HIV status and current antiretroviral therapy
• Body composition data (DXA, CT, or waist-to-hip ratio measurement)
• Review of fasting glucose and HbA1c (tesamorelin increases IGF-1 and may worsen glucose tolerance) [1]
• Pituitary history and exclusion of active malignancy
• Discussion of injection technique and site rotation

The FDA label explicitly states that glucose and HbA1c should be monitored periodically during tesamorelin therapy because of the drug's insulin-sensitizing and GH-stimulating effects [1].

Monitoring Cadence

The American Association of Clinical Endocrinology (AACE) recommends periodic IGF-1 monitoring for any patient on GH-axis therapy to avoid supraphysiologic levels [16]. For tesamorelin, the prescribing information recommends assessing VAT response at approximately 6 months to determine whether continued therapy is warranted [1]. Patients who do not show a meaningful reduction in abdominal girth or imaging-confirmed VAT reduction at 6 months should reassess with their prescriber.

Insurance, Prior Authorization, and Cost in Colorado

Egrifta SV carries a list price that, without insurance, reaches several thousand dollars per month. Prior authorization is the standard step for both commercial and public-payer coverage in Colorado.

Commercial Insurance

Most Colorado commercial plans (Anthem, Cigna, Aetna, Denver Health Medical Plan) treat Egrifta as a specialty tier medication. Prior authorization requires documentation of HIV diagnosis, lipodystrophy diagnosis, and, in most cases, a baseline VAT measurement or objective body composition assessment [15]. Some plans require a trial of lifestyle intervention before approving the drug.

Medicare and Medicaid

Medicare Part B may cover Egrifta when administered under a physician's supervision, while Part D covers self-injected supplies. Coverage determinations vary by plan. Health First Colorado (Medicaid) covers the drug with prior authorization for HIV-positive members meeting clinical criteria [15].

Patient Assistance

For uninsured or underinsured Colorado patients, Theratechnologies' EGRIFTAssist program offers co-pay support and connects patients with specialty pharmacy resources [6]. The program is accessible via the manufacturer's website and does not require Colorado-specific enrollment steps.

Prescriber and Pharmacy Licensing Requirements in Colorado

Both prescriber and pharmacy must hold active Colorado licenses for a tesamorelin prescription to be legally dispensed.

Prescriber Licensing

Colorado licenses physicians through the Colorado Medical Board (DORA Division of Professions and Occupations) [2]. Nurse practitioners and physician assistants hold prescriptive authority under their respective licensing boards. None of these licenses carry a specialty restriction on prescribing Egrifta. A primary care physician in Colorado may legally prescribe it provided the clinical criteria are met.

Pharmacy Licensing

All dispensing pharmacies must hold a current Colorado Board of Pharmacy license [2]. Out-of-state mail-order pharmacies must hold a non-resident pharmacy permit from the Colorado Board of Pharmacy to ship Egrifta to Colorado residents. The Colorado State Board of Pharmacy maintains an online license verification tool. Patients ordering from out-of-state specialty pharmacies should confirm non-resident permit status before filling.

Key Safety Information Colorado Patients Should Know

Egrifta is not a growth hormone product. It stimulates the pituitary gland to release GH in a pulsatile, physiologic pattern rather than delivering exogenous GH directly [1]. This mechanism is considered more physiologic than recombinant human GH (rhGH) therapy, and tesamorelin does not suppress the pituitary's own feedback loop in the way exogenous GH does [4].

Contraindications

The FDA label identifies four absolute contraindications: disruption of the hypothalamic-pituitary axis (from hypophysectomy, hypopituitarism, pituitary tumor, or head irradiation); active malignancy; pregnancy; and hypersensitivity to tesamorelin or mannitol [1]. Colorado prescribers should screen for all four before initiating therapy.

Drug Interactions

Tesamorelin may alter the metabolism of drugs processed by CYP450 enzymes by increasing GH and IGF-1 levels [1]. The FDA label notes that glucocorticoids may blunt tesamorelin's GH-stimulating effect, a relevant consideration for HIV patients on corticosteroid therapy [1]. Clinicians should review the full interaction profile via the FDA label before prescribing [1].